Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Omnicell, Inc. or Haemonetics Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Omnicell, Inc. and Haemonetics Corporation compare based on key financial metrics to determine which better meets your investment needs.

About Omnicell, Inc. and Haemonetics Corporation

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Latest Health Care Equipment & Supplies and Omnicell, Inc., Haemonetics Corporation Stock News

As of June 1, 2026, Omnicell, Inc. had a $2.0 billion market capitalization, compared to the Health Care Equipment & Supplies median of $344.7 million. Omnicell, Inc.’s stock is down 6.3% in 2026, down 3.7% in the previous five trading days and up 44.69% in the past year.

Currently, Omnicell, Inc.’s price-earnings ratio is 98.1. Omnicell, Inc.’s trailing 12-month revenue is $1.2 billion with a 1.7% net profit margin. Year-over-year quarterly sales growth most recently was 14.9%. Analysts expect adjusted earnings to reach $1.938 per share for the current fiscal year. Omnicell, Inc. does not currently pay a dividend.

As of June 1, 2026, Haemonetics Corporation had a $3.1 billion market cap, putting it in the 60th percentile of all stocks. Haemonetics Corporation’s stock is down 17.1% in 2026, down 0.6% in the previous five trading days and down 0.91% in the past year.

Currently, Haemonetics Corporation’s price-earnings ratio is 32.8. Haemonetics Corporation’s trailing 12-month revenue is $1.3 billion with a 7.3% net profit margin. Year-over-year quarterly sales growth most recently was 4.8%. Analysts expect adjusted earnings to reach $5.221 per share for the current fiscal year. Haemonetics Corporation does not currently pay a dividend.

How We Compare Omnicell, Inc. and Haemonetics Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Omnicell, Inc. and Haemonetics Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Omnicell, Inc. and Haemonetics Corporation Stock Value Grades

Company	Ticker	Value
Omnicell, Inc.	OMCL	D
Haemonetics Corporation	HAE	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Omnicell, Inc. has a Value Score of 37, which is Expensive. Haemonetics Corporation has a Value Score of 47, which is Average.

The Value Stock Winner: No Clear Winner

Neither Omnicell, Inc. or Haemonetics Corporation has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Omnicell, Inc. or Haemonetics Corporation is the better investment when it comes to value.

Omnicell, Inc. and Haemonetics Corporation’s Momentum Grades

Company	Ticker	Momentum
Omnicell, Inc.	OMCL	B
Haemonetics Corporation	HAE	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Omnicell, Inc. has a Momentum Score of 65, which is Strong. Haemonetics Corporation has a Momentum Score of 47, which is Average.

The Momentum Grade Winner: Omnicell, Inc.

As you can clearly see from the Momentum Grade breakdown above, Omnicell, Inc. is considered to have stronger momentum compared to Haemonetics Corporation. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Omnicell, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Omnicell, Inc. and Haemonetics Corporation’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Omnicell, Inc.	OMCL	C
Haemonetics Corporation	HAE	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Omnicell, Inc. has a Earnings Estimate Score of 54, which is Neutral. Haemonetics Corporation has a Earnings Estimate Score of 44, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Omnicell, Inc. or Haemonetics Corporation has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Omnicell, Inc. or Haemonetics Corporation is the better investment when it comes to estimate revisions.

Other Omnicell, Inc. and Haemonetics Corporation Grades

In addition to Momentum, Value and Estimate Revisions, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Omnicell, Inc. and Haemonetics Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Omnicell, Inc. or Haemonetics Corporation Stock?

Overall, Omnicell, Inc. stock has a Value Score of 37, Momentum Score of 65 and Estimate Revisions Score of 54.

Haemonetics Corporation stock has a Value Score of 47, Momentum Score of 47 and Estimate Revisions Score of 44.

Comparing Omnicell, Inc. and Haemonetics Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.